2020•Clinics and Research in Hepatology and GastroenterologyRequires access

Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial

Fabrizio Fabrizi, Roberta Cerutti, Rebeca García-Agudo, Cecilia Bellincioni, Giulia Porata, Giulia Frontini, Sami Aoufi-Rabih, Piergiorgio Messa

Open publisher page 17 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Open label, Dialysis, Virology, Population, Randomized controlled trial, Internal medicine, Environmental health

Back to paper search Browse research topics Original source

Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial — Research Paper | ScholarLens